

EFW
1637
\$

AMENDMENT TRANSMITTAL LETTER			ATTORNEY'S DOCKET NO. G-101US05REG
SERIAL NO. 10/051,681	FILING DATE January 16, 2002	EXAMINER Kenneth R. Horlick	GROUP ART UNIT 1637
INVENTION Treatment of CNS Disorders Using D-Amino Acid Oxidase and D-Aspartate Oxidase Antagonists			

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is an amendment in the above-identified application.



Small entity status of this application under 37 CFR 1.27 has been established by a verified statement previously submitted.

Applicant claims small entity status.

A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.

No additional fee is required.

☒ The fee has been calculated as shown below:

(1) (2) (3) SMALL ENTITY OTHER THAN A SMALL ENTITY

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	* 33	MINUS	** 20	5
INDEP.	* 9	MINUS	*** 5	4
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM				0

RATE	ADDIT. FEE
\$ 9	\$0.00
\$43	\$0.00
\$145	\$0.00
Total addit. fee	\$0.00

OR

RATE	ADDIT. FEE
\$18	\$234.00
\$86	\$344.00
\$290	\$ 0.00
Total addit. fee	\$578.00

OR

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the Highest No. Previously Paid For IN THIS SPACE is less than 20, enter "20."

*** If the Highest No. Previously Paid For IN THIS SPACE is less than 3, enter "3."

The Highest No. Previously Paid For (Total or Indep.) is the highest number found in the appropriate box in Col. 1.

- ☒ Please charge my Deposit Account No. 19-0065 in the amount of \$ 578.00.
- ☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-0065. Two additional copies of this Letter are enclosed.
- ☒ Any additional filing fees required under 37 CFR 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.

May 12, 2004

(date)

(signature)

Frank C. Eisenschenk, Ph.D., Reg. No. 45,332

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on May 12, 2004.

Frank C. Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

ELECTION UNDER 35 U.S.C. §121
AND SUPPLEMENTAL PRELIMINARY
AMENDMENT
Patent Application
Examining Group 1637
Docket No. G-101US05REG
Serial No. 10/051,681



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Kenneth R. Horlick
Art Unit : 1637
Applicants : Daniel Cohen, Ilya Chumakov
Serial No. : 10/051,681
Filed : January 16, 2002
Conf. No. : 1458
For : Treatment of CNS Disorders Using D-Amino Acid Oxidase and D-Aspartate Oxidase Antagonists

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

ELECTION UNDER 35 U.S.C. §121 AND
SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

A Petition and Fee for a one-month Extension of Time through and including May 12, 2004, accompanies this Election.

In response to the written Restriction Requirement dated March 12, 2004 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 1-9 and 12-18), without traverse.

Prior to examination, Applicants respectfully request that the subject application be amended as follows: